Complex Medicinal Products - the Other 'Biosimilar'

Posted 21 December 2016 By Douglas W. Balogh, PhD

placeholder+image This article discusses Non-Biological Complex Drugs (NBCDs) and how FDA and other regulatory agencies review and approve generic forms of these products.

Share this article:

Categories: Generic drugs, Regulatory strategy, Submission and registration, Features, US, FDA

Tags: Non-Biological Complex Drugs, NBCD

Regulatory Exchange: Latest Updates From the Community